Stiris Research Announces Database Lock in Phase 1b Hypoglycemic Clamp Trial

London, ON — May 25, 2022 —

Stiris Research Inc. (“Stiris”), an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announces the successful completion of database lock on its Phase 1b pharmacodynamic evaluation study in Type 1 Diabetics (T1D).

“Reaching a database lock milestone is always a great culmination of all the hard work involved in running a study from start to end. Congratulations to the entire study team for demonstrating the importance of coordination, collaboration, and cooperation in conducting a demanding study during a pandemic. We now look forward to analyzing the data collected and would like to see the results have a positive outcome for patients,” said Urszula Bartlomiejska, Project Manager, Stiris Research, Inc.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.